• 1.

    Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:22952306. doi: 10.1056/NEJMoa1811744

  • 2.

    Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:21172128. doi: 10.1056/NEJMoa1504720

  • 3.

    Wiviott SD, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380:347357. doi: 10.1056/NEJMoa1812389

  • 4.

    Neal B, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377:644657. doi: 10.1056/NEJMc1712572

  • 5.

    Pham PT, et al. Diabetes mellitus after solid organ transplantation. In: Endotext [Internet], edited by Feingold KR, et al. South Dartmouth, Massachusetts, MDText.com, Inc., 2000–2019 Apr 15. https://www.ncbi.nlm.nih.gov/books/NBK378977/

    • Search Google Scholar
    • Export Citation
  • 6.

    Halden TAS, et al. Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus. Diabetes Care 2019; 42:10671074. doi: 10.2337/dc19-0093

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Mahling M, et al. Sodium-glucose cotransporter 2 (SGLT2) inhibition in kidney transplant recipients with diabetes mellitus. Kidney Blood Press Res 2019; 44:984992. doi: 10.1159/000501854

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Rajasekeran H, et al. Use of canagliflozin in kidney transplant recipients for the treatment of type 2 diabetes: A case series. Diabetes Care 2017; 40:e75e76. doi: 10.2337/dc17-0237

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    AlKindi F, et al. Outcomes of SGLT2 inhibitors use in diabetic renal transplant patients. Transplant Proc 2020; 52:175178. doi: 10.1016/j.transproceed.2019.11.007

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Cehic MG, et al. Efficacy and safety of empagliflozin in the management of diabetes mellitus in heart transplant recipients. Transplant Direct 2019; 5:e450. doi: 10.1097/TXD.0000000000000885

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Heerspink HJL, et al. Nephrol Dial Transplant 2020; 35:274282. doi: 10.1093/ndt/gfz290

  • 12.

    Schwaiger E, et al. Empagliflozin in posttransplantation diabetes mellitus; a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety. Am J Transplant 2019; 19:907919. doi: 10.1111/ajt.15223

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Halden TS, et al. Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus. Diabetes Care 2019; 42:10671074.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14.

    Hecking M, Jenssen T. Considerations for SGLT2 inhibitor use in post-transplantation diabetes. Nat Rev Nephrol 2019; 15:525526.

SGLT2 Inhibitors in Solid Organ Transplant Recipients with Type 2 Diabetes Mellitus

Anju YadavAnju Yadav, MD, FASN, is an assistant professor of nephrology at Thomas Jefferson University Hospital, Philadelphia.

Search for other papers by Anju Yadav in
Current site
Google Scholar
PubMed
Close
Restricted access
Save